P. Day

发表

Structure-based identification of a ricin inhibitor.

G. Milne, A. Monzingo, J. Robertus, 1997, Journal of molecular biology.

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

G. Chessari, P. Williams, E. J. Lewis, 2015, Journal of medicinal chemistry.

Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery

Paul N. Mortenson, Melanie V. Leveridge, S. Teague, 2014 .

Acetyl coenzyme A binding by chloramphenicol acetyltransferase: long-range electrostatic determinants of coenzyme A recognition.

W. V. Shaw, A. Leslie, P. Day, 1992, Biochemistry.

Cell Surface Transporters and Novel Drug Developments

P. Day, Natasha Carmichael, 2022, Frontiers in Pharmacology.

Binding of ricin A-chain to negatively charged phospholipid vesicles leads to protein structural changes and destabilizes the lipid bilayer.

T. Pinheiro, L. Roberts, J. Lord, 2002, Biochemistry.

Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model.

J. Kronauge, P. Day, A. G. Jones, 1997, Nuclear medicine and biology.

Structure and activity of an active site substitution of ricin A chain.

J. Pascal, A. Frankel, A. Monzingo, 1996, Biochemistry.

Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone

Jose Cosme, Clemens Vonrhein, C. Vonrhein, 2004, Science.

Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site.

W. V. Shaw, A. Leslie, M. Sutcliffe, 1995, Journal of molecular biology.

Ribosome-mediated Folding of Partially Unfolded Ricin A-chain*

S. Radford, P. Stockley, L. Roberts, 2000, The Journal of Biological Chemistry.

An Interaction between Ricin and Calreticulin That May Have Implications for Toxin Trafficking*

J. Wesche, L. Roberts, J. Lord, 2001, The Journal of Biological Chemistry.

Differences in cytotoxicity of native and engineered RIPs can be used to assess their ability to reach the cytoplasm.

J. Robertus, J. K. Suh, M. Svinth, 1998, Biochemical and biophysical research communications.

Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers.

W. V. Shaw, I. Murray, P. Day, 1995, Biochemistry.

The low lysine content of ricin A chain reduces the risk of proteolytic degradation after translocation from the endoplasmic reticulum to the cytosol.

Daniel C. Smith, L. Roberts, J. Lord, 2002, Biochemistry.

Synthesis and biodistribution of 64Cu-labeled monocationic diiminedioxime copper(II) complexes.

S. Treves, J. Kronauge, P. Day, 1998, Nuclear medicine and biology.

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

Gianni Chessari, Brent Graham, Jose Cosme, 2010, Journal of medicinal chemistry.

Kinetic analysis of barley chitinase.

E. Marcotte, J. Robertus, Y. Honda, 1997, Archives of biochemistry and biophysics.

Insertional mutagenesis of ricin A chain: a novel route to an anti-ricin vaccine.

Daniel C. Smith, L. Roberts, J. Lord, 2004, Vaccine.

The deoxyribonuclease activity attributed to ribosome-inactivating proteins is due to contamination.

L. Roberts, J. Lord, P. Day, 1998, European journal of biochemistry.

Crystal structure of human CDK4 in complex with a D-type cyclin

Rajiv Chopra, Jeff Yon, Christoph Lengauer, 2009, Proceedings of the National Academy of Sciences.

2.8‐Å crystal structure of a nontoxic type‐II ribosome‐inactivating protein, ebulin l

J. Pascal, A. Monzingo, J. Robertus, 2001, Proteins.

L‐&bgr;‐N‐methylamino‐L‐alanine (BMAA) nitrosation generates a cytotoxic DNA damaging alkylating agent: An unexplored mechanism for neurodegenerative disease

G. Margison, G. Margison, P. Day, 2017, Neurotoxicology.

Modulation of the G0 to S phase transit time by insulin: Potential involvement of protein phosphorylation

P. Day, R. Kletzien, P. Day, 1980, Journal of cellular physiology.

Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP.

A. Sharff, H. Nar, J. Yon, 2007, Acta crystallographica. Section D, Biological crystallography.

The effect of mutations surrounding and within the active site on the catalytic activity of ricin A chain.

V. Fülöp, J. Lord, P. Day, 2004, European journal of biochemistry.

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO

J. Yon, T. Davies, P. Ward, 2014, PloS one.

Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).

C. Murray, Zehong Wan, V. Berdini, 2016, Journal of medicinal chemistry.

Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.

C. Murray, F. Holding, V. Berdini, 2016, Journal of medicinal chemistry.

Structural analysis of ricin and implications for inhibitor design.

A. Monzingo, J. Robertus, T. Hollis, 1996, Toxicon : official journal of the International Society on Toxinology.

An improved 191Os/191mIr generator using a hybrid anion exchanger.

S. Treves, P. Day, A. Packard, 1995, Nuclear medicine and biology.